

VOLTAGE-GATED SODIUM CHANNELS AND HYPERALGESIA

Josephine Lai,¹ Frank Porreca,^{1,2} John C. Hunter,³
and Michael S. Gold^{4,5}

¹Departments of Pharmacology and ²Anesthesiology, University of Arizona Health Sciences Center, Tucson, Arizona 85724; email: lai@u.arizona.edu, frankp@u.arizona.edu

³CNS&CV Research, Schering-Plough Research Institute, Kenilworth, New Jersey 07033; email: john.hunter@spcorp.com

⁴Departments of Oral and Craniofacial Biological Sciences and ⁵Anatomy and Neurobiology, University of Maryland, Baltimore, Maryland 21201; email: msg001@dental.umaryland.edu

Key Words inflammation, neuropathic pain, sensory neuron, local anesthetics, antiarrhythmics, anticonvulsants

Abstract Physiological and pharmacological evidence both have demonstrated a critical role for voltage-gated sodium channels (VGSCs) in many types of chronic pain syndromes because these channels play a fundamental role in the excitability of neurons in the central and peripheral nervous systems. Alterations in function of these channels appear to be intimately linked to hyperexcitability of neurons. Many types of pain appear to reflect neuronal hyperexcitability, and importantly, use-dependent sodium channel blockers are effective in the treatment of many types of chronic pain. This review focuses on the role of VGSCs in the hyperexcitability of sensory primary afferent neurons and their contribution to the inflammatory or neuropathic pain states. The discrete localization of the tetrodotoxin (TTX)-resistant channels, in particular Nav1.8, in the peripheral nerves may provide a novel opportunity for the development of a drug targeted at these channels to achieve efficacious pain relief with an acceptable safety profile.

INTRODUCTION

Voltage-gated sodium channels (VGSCs) play a fundamental role in the excitability of all neurons. They are located in the plasma membrane and mediate the influx of sodium ions into the cell in response to local membrane depolarization; sodium influx results in the generation of the action potential. Alteration in VGSC expression and/or function thus has a profound effect on the firing pattern of sensory primary afferent neurons as well as neurons in the central nervous system. Injury to sensory primary afferent neurons often results in abnormal, repetitive discharge or

exaggerated response to subsequent sensory stimuli. Such exaggerated response is believed to contribute to chronic inflammatory and neuropathic pains. Central projection neurons that relay sensory signals to the sensory cortex may also become hyperresponsive, a process termed central sensitization. Both physiological and pharmacological evidence implicate a critical role of VGSCs in the development and maintenance of hyperexcitability observed in primary afferent neurons following nerve and tissue injury. Importantly, use-dependent sodium channel inhibitors are clinically effective in the treatment of many types of chronic pain. This review focuses on VGSCs in sensory afferent neurons and their contribution to nerve and tissue injury-induced pain.

Voltage-Gated Sodium Channels

Each VGSC comprises a large alpha subunit (~ 260 kDa) and one or more beta subunits (33–36 kDa) (1) (Figure 1). The alpha subunit consists of four homologous domains (I–IV), each containing six transmembrane segments (S1–S6) and a




Figure 1 Schematic secondary structure of the family of VGSCs, their classification, tissue distribution, and functional characteristics.

pore-forming loop between segments V and VI. The alpha subunit contains all of the machinery necessary for a functional ion channel in addition to the ion pore, including the voltage sensor (in domain IV), an ion selectivity “filter,” and a segment responsible for fast inactivation (third intracellular loop between IIIS6 and IVS1, identifiable by the tripeptide motif, IFM). Thus, a single alpha subunit constitutes a functional VGSC. The alpha subunit also contains the majority of sites mediating pharmacological modulation of gating or permeation processes, e.g., the binding site for tetrodotoxin (TTX) resides in domain I. The alpha subunit also contains a number of phosphorylation sites, which enable relatively rapid modulation of channel gating properties (1). Beta subunits appear to serve a number of functions, including targeting and anchoring channels at specific sites in the plasma membrane and modulation of the gating properties of the alpha subunits (2). Genes encoding ten alpha subunits and three beta subunits have been identified (3). The tissue- and cell-specific expression of these channel subtypes can be critical in determining the heterogeneity and functional specialization of many types of cells, including the sensory neurons of the peripheral nervous system that propagate sensory or nociceptive signals to the brain and the spinal cord. Detailed reviews of this topic may be found elsewhere (4, 5).

Sensory Primary Afferent Neurons

Sensory neurons are a heterogeneous population of primary afferent neurons that subserve an array of unique functions, including proprioception, mechanosensation (vibratory, pressure), thermal sensation (cool, warm), as well as nociception. The cutaneous afferent, i.e., sensory neurons that innervate the skin and skeletal muscles, can be differentiated morphologically and functionally. Among these are myelinated, fast-conductance, large-diameter fibers called A-beta fibers, which have a low threshold for activation and mainly conduct information about innocuous touch; the thinly myelinated medium-velocity fibers called A-delta fibers, which are polymodal in nature; and the unmyelinated, slow-conductance small-diameter fibers called C fibers, most of which have high threshold for activation and transmit potentially damaging, noxious inputs. Among the population of nociceptive afferents, there are a number of unique subpopulations (6), including afferents responsive to noxious thermal stimuli (i.e., C-cold fibers); noxious thermal and mechanical stimuli (i.e., C-mechano-heat fibers); and noxious thermal, mechanical, and chemical stimuli (C-polymodal). This heterogeneity has implications for injury-induced pain, as observations indicate that subpopulations of afferents may be far more important than others for the expression of specific pain syndromes. For example, mechanically insensitive afferents (MIAs) appear to be critical for the prolonged burning sensation associated with the application of capsaicin, the pungent component of chili peppers (7).

The most direct way to correlate the expression of sodium channel subtypes and the biophysical properties of sensory neurons is to record from these neurons *in vivo*; determine their biophysical characteristics, such as stimulus response

properties and action potential conduction velocity; then assess the Na^+ channels present in the neuron by immunohistochemical or molecular biological techniques. Djouhri, Lawson, and coworkers have used this approach to describe the populations of sensory neurons that express $\text{Nav}1.7$ (8), $\text{Nav}1.8$ (9), and $\text{Nav}1.9$ (10). Characterization of sodium channel function in sensory neurons includes patch recording from teased fiber (11), isolated organ preparations (12), or by recording from the sensory neuron cell body in vitro. The most common of these is the isolated sensory neuron cell body preparation.

Based on data obtained *in vivo*, a number of criteria have been used to distinguish subpopulations of sensory neurons. These include cell body size (13), histological properties (14–20), chemosensitivity (14, 15), and electrophysiological properties (14, 15). Cell body size is used as a criterion based on data from cutaneous afferents indicating that there is a correlation between cell body size and action potential conduction velocity: Neurons with a small cell body diameter tend to give rise to slowly conducting axons, whereas neurons with a large cell body diameter tend to give rise to rapidly conducting axons (21–23). Thus, neurons with a small cell body diameter are considered putative nociceptors (i.e., conduct high threshold noxious input), whereas neurons with a large cell body diameter are considered likely nonnociceptive in nature. Electrophysiological properties may also be used to distinguish nociceptive from nonnociceptive afferents. Because all high-threshold afferents, whether they have rapidly or slowly conducting axons, have an inflection or “hump” on the falling phase of the somal action potential (24), neurons with a hump are likely to be nociceptive, and the converse is also true.

Voltage-Gated Sodium Channels in Sensory Neurons

Use of *in situ* hybridization and reverse transcriptase–coupled polymerase chain reaction (RT-PCR) techniques indicate that nine of the ten alpha subtypes (25, 26) and all three beta subtypes (27), plus the splice variant of beta 1, beta1A (28), of sodium channels are present in sensory neurons. Although $\text{Nav}1.6$ and $\text{Nav}1.7$ are present in virtually all sensory neurons, $\text{Nav}1.1$, 1.2, 1.8, and 1.9 are differentially expressed among subpopulations of sensory neurons (25). $\text{Nav}1.1$ is preferentially expressed in large-diameter sensory neurons, $\text{Nav}1.8$ is highly expressed in small-diameter neurons and to a lesser extent in subpopulations of medium- and large-diameter neurons, whereas $\text{Nav}1.9$ is only present in small-diameter neurons. $\text{Nav}1.2$ is variably expressed among sensory neurons, with most cells lacking a detectable hybridization signal. $\text{Nav}1.3$ (29) and 1.5 (26) are developmentally regulated such that they are highly expressed in embryonic sensory neurons, but expressed at very low levels in adult sensory neurons. $\text{Nav}1.5$ appears to be present in less than 5% of sensory neurons in the adult rat.

Results from immunohistochemical studies indicate that VGSC subtypes are differentially distributed throughout the neuron. For example, $\text{Nav}1.6$ appears to be the channel most highly localized to nodes of Ranvier (30), whereas $\text{Nav}1.7$,

1.8, and 1.9 are not. In contrast, $\text{Nav}1.7$ appears to be preferentially expressed in axon terminals (31), $\text{Nav}1.8$ is preferentially expressed in the cell body and possibly the terminal arbor, whereas $\text{Nav}1.9$ is expressed throughout neurons that give rise to unmyelinated axons (32). Finally, as discussed below, there is evidence that the cellular distribution of several of these channels changes following injury.

Electrophysiological characterization of VGSCs present in sensory neurons, in combination with the neurotoxin TTX, indicates that there are two general classes of current in sensory neurons: one is blocked by TTX (TTX-sensitive or TTX-S) and the other is insensitive to TTX (TTX-resistant or TTX-R). TTX-S currents are blocked by TTX at concentrations in the low nanomolar range. These VGSCs tend to have a low threshold for activation (between -55 and -40 mV), are rapidly activating, and are rapidly inactivating. Approximately 50% of these channels are available for activation at potentials close to resting membrane potential (~ 65 mV) (33). Most TTX-S currents present in sensory neurons recover from inactivation with a relatively slow time course. However, as discussed below, following nerve injury, there is an increase in the rate of recovery that appears to coincide with changes in the expression pattern of TTX-S VGSCs present in sensory neurons (34).

VGSCs that are TTX-R have been further subdivided into several different classes of ionic current on the basis of distinct biophysical properties. One of these TTX-R currents has similar biophysical properties to those of TTX-S channels, with a low threshold for activation and relatively rapid rates of activation and inactivation. This low-threshold TTX-R current has been referred to as TTX-R3 (35) or fast TTX-R current (36). An additional TTX-R current with very low thresholds for activation has also been described [i.e., TTX-R4 (36)]. A more recent analysis of the low-threshold TTX-R current in sensory neurons suggests that this current is carried by $\text{Nav}1.5$ (26).

A second TTX-R current is resistant to TTX at concentrations $> 10 \mu\text{M}$ (33, 35, 37–39). This current has a high threshold for both activation (~ -36 mV) and steady-state inactivation, activates and inactivates relatively slowly, but recovers from inactivation or repriming rapidly (33). Furthermore, data from these studies show that this current accounts for the high activation threshold observed in nociceptive afferents. Because the current is still largely available for activation in the presence of sustained membrane depolarization and recovers from inactivation rapidly with membrane hyperpolarization, these properties suggest that this current can sustain low levels of activity when other channel subtypes are inactivated by the depolarization potential (39). This high-threshold TTX-R current has been referred to as TTX-R1 [(35), see also References 36, 40]. There is compelling evidence to suggest that $\text{Nav}1.8$ underlies this high-threshold TTX-R current. Critically, the nuclear injection of $\text{Nav}1.8$ cDNA into sensory neurons isolated from $\text{Nav}1.8$ knockout mice results in the expression of a TTX-R current identical to TTX-R1 (41).

A third TTX-R current is also resistant to TTX at concentrations $> 10 \mu\text{M}$. This current has very unique biophysical properties compared to the rest of the

family of VGSCs. It has a very low threshold for activation (between -90 and -70 mV) and an availability curve with a midpoint of ~ -44 mV (40). These two properties enable current activation over a large voltage range and can have a profound influence on neuronal excitability (42). This current has been referred to as a persistent current. Because the activation rate of this current is very slow, it is unlikely to contribute to the action potential but may contribute to the determination of the resting membrane potential and membrane depolarization associated with subthreshold stimuli (43). $\text{Nav}1.9$ appears to be the channel underlying this persistent current because (a) there is a good correlation between the properties of neurons that express the persistent current and those that express $\text{Nav}1.9$ (32, 40), (b) this current is detectable in dorsal root ganglia (DRG) neurons from $\text{Nav}1.8$ knockout mice, and (c) the sequence of $\text{Nav}1.9$ predicts a channel that will be resistant to TTX (44, 45).

Functional characterization of specific VGSCs in sensory neurons has been inhibited by the lack of selective channel blockers. Classic channel blockers, such as local anesthetics, antiepileptics, and membrane stabilizers, show little specificity among channel subtypes (46, 47). Although pharmacological tools do not yet enable a functional characterization of specific VGSCs in sensory neurons, several novel approaches in combination with available pharmacological tools have yielded important results. First, it is clear that TTX-S channels mediate action potential conduction along both myelinated and unmyelinated axons. This is based on the observation that TTX application to distal axons completely blocks conduction in the vast majority of studies reported to date (12, 24). Thus, even though there is evidence for functional TTX-R channels in axons (11), the density of these channels appears to be insufficient to mediate conduction in the majority ($>92\%$) of unmyelinated and all myelinated axons (48). Given that rapid signaling of nociceptive stimuli requires action potential conduction, this observation illustrates a basis for the effectiveness of blocking TTX-S channels for pain control. Second, it is also clear that the TTX-R channel $\text{Nav}1.8$ contributes to the somal action potential of high threshold sensory neurons *in vivo* (24). In the presence of sustained membrane depolarization, resulting in the inactivation of TTX-S, $\text{Nav}1.8$ is sufficient to enable action potential generation in the majority of high-threshold afferents (49). However, as is more often the case, $\text{Nav}1.8$ appears to work in conjunction with TTX-S currents in the generation of action potentials. In such cases, the higher threshold for activation and the slower rates of activation and inactivation enable $\text{Nav}1.8$ to have a unique impact on the action potential waveform. TTX-R channels only contribute significantly to ion flux at later stages of the action potential, most importantly during the falling phase (50). At this stage, these channels appear to delay membrane repolarization enabling substantial Ca^{2+} influx. This Ca^{2+} influx has been shown to regulate a number of cellular processes and may be important for initiating transcriptional changes in nociceptive afferents in response to injury.

There is evidence that $\text{Nav}1.8$ channels are present and functional in peripheral terminals of nociceptive afferents. Brock and colleagues used an *in vitro*

preparation to study corneal afferents (12, 51, 52). These investigators observed that TTX-R channels mediated action potential initiation in polymodal nociceptive afferents, and that these initiation sites are very close to, if not at, the terminal endings (51). Finally, there is evidence that TTX-R currents may contribute to the release of transmitter from the central terminals of nociceptive afferents. This evidence comes from an *in vitro* preparation utilized to study synaptic interactions between primary afferent and dorsal horn neurons (53). In this preparation, it appears that ATP released from the primary afferent terminal is able to act back on the afferent terminal to facilitate additional release of glutamate. Importantly, the additional glutamate release was dependent on active conduction in the afferent terminal that, in turn, was dependent on the activation of TTX-R channels in the afferent terminal.

SODIUM CHANNELS AND HYPERALGESIA

Somatic/Cutaneous Inflammatory Hyperalgesia

Tissue injury results in local inflammation. Pain is one of the cardinal signs associated with this inflammation, and this pain reflects an increase in the excitability of afferent neurons innervating the injured tissue. This increase in excitability reflects the actions of a number of inflammatory mediators, including ATP, bradykinin, serotonin, cytokines such as TNF alpha, and prostaglandins. That analgesic agents, such as the nonsteroidal antiinflammatory drugs (NSAIDs), act to inhibit the production of prostaglandins from arachidonic acid by blocking cyclo-oxygenases (COX) (54) and are highly efficacious in alleviating inflammatory hyperalgesia (55) suggests that prostaglandins are critical inflammatory mediators that promote pain.

The Effect of Prostaglandins on Sensory Primary Afferent

Prostaglandins are often described as a prototypic hyperalgesic agent because they produce hyperalgesia and/or nociceptor sensitization while producing little direct activation of nociceptive terminals. Prostaglandins have been shown to sensitize nociceptors to all modes of stimuli tested, including mechanical, thermal, and chemical. For example, a continuous infusion of prostaglandin E₂ (PGE₂) increased the frequency of bradykinin-evoked action potentials recorded from the plantar nerve (56) or from the saphenous nerve (57). Several lines of evidence suggest that prostaglandins sensitize primary afferent neurons through a direct action on the sensory neurons. This evidence includes (a) the presence of receptors on the sensory neurons, (b) time course for behavioral changes, (c) absence of other detectable changes in tissue, and probably most compelling, (d) the demonstration of sensitization of isolated neurons *in vitro*. Importantly, use of the isolated neuron *in vitro* has enabled identification of mechanisms underlying the actions of inflammatory mediators, such as prostaglandins.

The Effect of PGE₂ on Voltage-Gated Sodium Channels

PGE₂ modulates TTX-R sodium current in sensory neurons in a manner consistent with an underlying mechanism of sensitization; the current activates at more hyperpolarized potentials and the magnitude of the current is increased as are its rates of activation and inactivation (49). As discussed above, TTX-R sodium currents are essential for action potential generation in the majority of nociceptive neurons. Thus, the ability of PGE₂ to modulate the activity of these channels presents a highly effective mechanism by which PGE₂ can selectively enhance the excitability of the nociceptive neurons.

Support for a causal relationship between PGE₂-induced hyperalgesia and TTX-R sodium current has been provided by using an antisense deoxynucleotide (ODN) that specifically disrupts the synthesis (“knockdown”) of one of the TTX-R VGSCs, Nav1.8 in the DRG *in vivo* (58). Antisense, but not a control mismatch, ODN treatment reduces the expression of Nav1.8 by ~50%, and rats treated with the antisense ODN show a significant decrease in PGE₂-induced mechanical hyperalgesia (58). Because Nav1.8 is normally expressed predominantly in unmyelinated, nociceptive C fibers, these data show that acute PGE₂-induced hyperalgesia is mediated by nociceptive C fiber activity that is sustained by TTX-R sodium current. The data also implicate Nav1.8 as the critical VGSC subtype that is necessary for the initiation of hyperalgesia.

The Effect of Other Acute Inflammatory Mediators on Voltage-Gated Sodium Channels

To date, a number of acute inflammatory mediators, including adenosine (59), serotonin/5-hydroxytryptamine (5-HT) (60–62), bradykinin (57, 63), endothelin-1 (64–68), and plasma epinephrine (69), have also been demonstrated to directly modulate the excitability of primary afferents. Their direct action on primary afferent indicates that the receptors for these mediators must be expressed on nociceptive neurons. These mediators, with the exception of bradykinin (and possibly ET-1), have been shown to modulate the activity of TTX-R sodium current in a manner similar to that seen for PGE₂ (59, 60, 62, 64). Modulation of TTX-R sodium current thus appears to be a common mechanism that underlies the sensitizing effect of multiple inflammatory mediators.

Neurotrophic Factors and their Effect on Voltage-Gated Sodium Channels

In addition to the inflammatory mediators listed above, which act to alter the activity of VGSCs locally, there are a number of mediators that influence neuronal excitability by regulating gene transcription. The most extensively studied of these molecules, at least with respect to their role in nociceptive processing, include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial cell-derived neurotrophic factor (GDNF) and related factors. During development,

these compounds act as survival factors. In the adult, they appear to control the phenotype of sensory neurons. Because the concentration of these compounds, particularly that of NGF, is increased in the presence of inflammation, NGF is able to drive phenotypic changes in sensory neurons innervating the site of injury. Consistent with this suggestion is the observation that peripheral administration of NGF induces a localized, delayed hyperalgesia that is long lasting (70–72), suggesting that NGF induces the expression of proteins in the sensory neurons that enhance their excitability. There is evidence that NGF stimulates an upregulation of $\text{Na}_V1.8$ in small DRG cells as it enhances the density of TTX-R current in specific subpopulations of sensory neurons (73). In cultured neurons, NGF acutely enhances the excitability of small DRG neurons by enhancing TTX-R current (74). Thus, NGF may enhance nociceptive afferent excitability, in part, by exerting both an acute influence on the gating of TTX-R sodium current (its contribution from $\text{Na}_V1.8$ and/or $\text{Na}_V1.9$ has not been defined) and a prolonged influence by an increased expression of $\text{Na}_V1.8$. On the other hand, NGF has no effect on the expression of $\text{Na}_V1.9$ (75). Thus, the increase in TTX-R is likely to be due to the upregulation of $\text{Na}_V1.8$.

NGF also stimulates the synthesis of BDNF in DRG neurons positive for NGF receptors, i.e., *trkA*-positive cells (76). Thus, BDNF is a transmitter in afferent fibers. The function of BDNF has been derived mainly from CNS studies, where BDNF may induce long-term potentiation and may evoke neuronal excitation by activating a sodium current (77). It was shown recently that BDNF may stimulate $\text{Na}_V1.9$ through a direct interaction between its activated receptor, called *trkB*, and $\text{Na}_V1.9$ in the central nervous system (78). However, because BDNF has not been found to alter sodium currents in the DRG cells (79), it has yet to be determined whether such action plays any role in inflammatory hyperalgesia.

Experimental Models of Inflammatory Hyperalgesia

Although the pharmacological and *in vitro* approaches described above have provided compelling evidence that implicate TTX-R sodium channels as an underlying mechanism of nociceptive hypersensitivity, they do present the caveat that the concentrations used in the analyses may not be physiologically relevant (particularly the doses of neurotrophic factors). Thus, the role of TTX-R in inflammatory hyperalgesia has to be validated in experimental models that more closely resemble clinical conditions. A large literature has elucidated many of the mechanisms of cutaneous inflammatory hyperalgesia by employing animal models in which inflammation is induced, typically in a hind limb, by subcutaneous administration of a small amount of a chemical reagent that stimulates a local inflammatory response. The most common reagents used include formalin, carrageenan (a seaweed extract), or complete Freund's adjuvant (CFA). Although these reagents all cause local tissue damage as indicated by mast cell degranulation, neutrophil and macrophage infiltration, plasma extravasation, or tissue necrosis, the extent and the characteristics of the injury, as well as the duration of hyperalgesia, vary substantially among these models. Models of neurogenic inflammation have also been

developed by the local administration of algogenic substances, such as capsaicin, which activate the release of excitatory neurotransmitters (e.g., substance P) from peripheral nociceptive termini that, in turn, stimulate an immune response.

Collective data from these studies also support a role of TTX-R sodium channels in inflammatory hyperalgesia. First, carrageenan- as well as CFA-induced hyperalgesia give rise to a significant upregulation of TTX-R current (79, 80) and the expression of Nav1.8 in the DRG cells (79, 81). Both carrageenan and CFA stimulate the production of NGF in immune cells (82, 83), suggesting that NGF production may be linked to the chemical-induced upregulation of Nav1.8 (73, 84). Second, the use of antisense ODNs that specifically target Nav1.8 to knockdown (i.e., reduce) the expression of this channel subtype in the lumbar DRG is effective in preventing the hyperalgesia measured four days after injection of CFA unilaterally into the rat hind paw (85). Similar results were obtained with an experimental model of urinary bladder inflammation, where knockdown of Nav1.8 was effective in attenuating the persistent inflammation-induced sensitization of bladder C fibers (86). Thus, Nav1.8 appears to contribute not only to the initiation of inflammatory hyperalgesia, but also to its maintenance.

Although the bulk of the data collected to date implicate a role for Nav1.8 in inflammatory hyperalgesia, it should be noted that there is also evidence for contribution of other channels, including Nav1.9 and Nav1.7. Recent evidence suggests that Nav1.9 also may be a target for modulation by inflammatory mediators, as the persistent current is dramatically increased following G-protein activation with the nonhydrolyzable GTP analog, GTP γ S (42). The GTP γ S-induced increase in persistent current was apparently sufficient to induce spontaneous activity in some neurons. Other lines of evidence implicating a potential role for Nav1.9 come from studies involving neurotrophic factors and channel expression. Specifically, NGF and GDNF induce increase in Nav1.9 expression (75). Evidence in support of a role for Nav1.7 comes from the observation that a brief exposure of NGF results in a dramatic redistribution of the channel to peripheral terminals of sprouting axons (87). It is also worth noting that in at least one *in vitro* study designed to identify mechanisms underlying 5-HT-induced increases in excitability, an increase in a TTX-S current was observed in some neurons (60).

SODIUM CHANNELS IN NEUROPATHIC PAIN

VGSCs in sensory neurons are thought also to play a critical role in a number of chronic, painful neuropathies that arise from injury to peripheral nerves. Symptoms of neuropathic pain include abnormal hypersensitivity to innocuous touch (allodynia) and noxious mechanical or thermal stimulation (hyperalgesia). Clinical neuropathic pain is often intractable and can arise from a variety of disease states (e.g., diabetic neuropathy, trigeminal neuralgia, postherpetic neuralgia, AIDS) or traumatic injuries, nerve compression, or chemotherapy.

It has long been appreciated that physical injury to peripheral nerves (e.g., sciatic nerve branches that innervate the foot) that is mimicked experimentally by

transection of the nerves' axon, results in rapid redistribution of VGSCs along the axon and dendrites, and spontaneous firing of the injured nerve (88, 89). The alteration in the excitability of the injured nerve is considered to be critical for the incidence of spontaneous pain in the absence of external stimuli (90). As the activity of VGSCs is necessary for action potential generation in all neurons, the changes in VGSCs associated with a transected nerve implicate a role of VGSCs in the hyperexcitability of the injured nerve.

It is well established that both TTX-R and TTX-S sodium currents are altered upon nerve transection, based on functional and gene expression analysis (44, 91–95). However, the relationship between changes in channel expression and changes in neuronal excitability is tenuous. A recent study involving transection of the vagus neurons demonstrates that axotomy-induced changes in TTX-R and TTX-S currents result in a decrease in excitability (96). Furthermore, given that partial nerve injuries are the ones most commonly associated with the development of pain, the relevance of the nerve transection model to clinical conditions of neuropathic pain arising from injury to peripheral nerve is less clear. However, data from other experimental models of peripheral nerve injury, as well as pharmacological evidence, suggest that the VGSC is a reasonable target for the treatment of neuropathic pain (see below). We limit our discussion to findings obtained from the models of surgically induced injuries to the sciatic nerve (97–101) because they represent the most commonly used models from which our current state of knowledge on the VGSC in neuropathic pain has been derived.

TTX-S and TTX-R Sodium Currents in Neuropathic Pain

The first sciatic nerve injury model involves a complete transection of the sciatic nerve. Because the sciatic nerve is comprised of afferents with cell bodies mainly in L4 and L5 ganglia, such an injury directly damages ~50% of the neurons in each ganglion. Such injury induces a rapid (days) onset of spontaneous, ectopic discharge from the site of injury, which, unlike activities observed in the presence of inflammation, is primarily carried by rapidly conducting A fibers. In a partial nerve injury model where only the L5 or the L5 and L6 spinal nerves are transected or tightly ligated, similar changes in the A fiber activity are restricted to the injured DRG (102–105) but not among the population of uninjured afferent from L4 (105). In the injured DRG, a significant upregulation of TTX-S current and a reduction in the TTX-R current in the small DRG are observed (34, 48). The increase in TTX-S is thought to be due to an enhanced expression of the channel subtype $\text{Na}_v1.3$, which is normally expressed at very low levels in the DRG of adult rats (29, 92, 106). The downregulation of TTX-R in the small DRG is due to decreased expression of the $\text{Na}_v1.8$ and $\text{Na}_v1.9$ subtypes (44, 94, 95).

$\text{Na}_v1.3$, Ectopic Discharge, and Neuropathic Pain

The evidence that supports a role for $\text{Na}_v1.3$ in mediating ectopic activity in the injured neurons is based on the following observations: First, the channel is

dramatically upregulated following nerve injury; second, the biophysical properties of the channel should enable the channel to support higher rates of activity; and third, nerve injury is associated with an increase in membrane potential oscillations that appear to underlie spontaneous activity, and these oscillations are TTX-S. Ectopic discharge (and thus $\text{Nav}1.3$ expression) has been proposed to underlie neuropathic pain because the time course for the development of membrane potential oscillations and ectopic activity correlates very well with the time course for the development of neuropathic pain behavior. Furthermore, the ectopic activity can be suppressed by sodium channel blockers such as lidocaine, which is clinically effective in treating neuropathic pain (see below). A recent study using pharmacological doses of GDNF to prevent sensory hypersensitivity in nerve-injured rats showed that this effect was concomitant with a block of A fiber ectopic discharge and normalization of $\text{Nav}1.3$ expression in the injured DRG (105).

On the other hand, lidocaine blocks all VGSCs and is not selective for $\text{Nav}1.3$, whereas GDNF normalizes the nerve injury-induced changes in the expression of many other proteins besides $\text{Nav}1.3$ in the DRG and spinal cord (107); thus, these drugs lack the target specificity to provide a definitive link between $\text{Nav}1.3$ expression and neuropathic pain. Furthermore, $\text{Nav}1.3$ is a TTX-S channel, but TTX applied to the injured nerve only partially reverses neuropathic pain behavior (108).

Some data also question whether $\text{Nav}1.3$ expression alone is sufficient for the onset of ectopic activity (e.g., the channel is upregulated in small DRG neurons, but they do not become spontaneously active) (96, 102, 105). The role of ectopic discharge in the manifestation of neuropathic pain is also not clear. Ectopic activity is exclusively associated with transected fibers, which are incapable of transmitting evoked sensory input. Neuropathic pain states, on the other hand, are generally measured in animal models as diminished response thresholds from evoked stimulation. Furthermore, in at least one experimental nerve injury model, ectopic activity of the injured fibers is highest soon after injury, but is significantly diminished within one week by almost 75% (103), whereas neuropathic pain behavior in the injured animal is maintained at the same level for many months (104, 109). There is also a growing body of evidence implicating a role of the remaining uninjured primary afferent of the sciatic nerve in maintaining sensory hypersensitivity (see below). Thus, ectopic activity of the injured neurons may be insufficient for the manifestation of neuropathic pain, at least as measured routinely in experimental models.

Nav1.8 and Neuropathic Pain

A knockdown of $\text{Nav}1.8$ in neuropathic rats in a model of mononeuropathy (L5/L6 spinal nerve ligation injury) effectively reverses neuropathic pain, bringing the sensory thresholds to thermal and tactile stimuli back to control levels (48, 110). This approach provides direct evidence that the activity of a sodium channel subtype in the sensory primary afferent is necessary for the expression of neuropathic pain.

It also suggests that primary afferent fibers that contain functional $\text{Nav}1.8$ after nerve injury may be “sensitized.” The important role of $\text{Nav}1.8$ in action potential generation and the additional observation that this channel subtype also enables the DRG cells to fire repetitively upon stimulation provide functional evidence to support such a hypothesis (111).

As mentioned above, injured primary afferents show a significant downregulation of $\text{Nav}1.8$; thus, the site of action of $\text{Nav}1.8$ is not likely to be in the injured nerve fibers. In the adjacent uninjured L4 DRG cells, however, the level of expression of $\text{Nav}1.8$ (95) and the density and kinetics of the TTX-R current (48) are not different from control, suggesting that the expression of $\text{Nav}1.8$ is maintained. However, a significant upregulation of the channel protein is apparent by day 2 after injury in the sciatic nerve (48). The upregulation of $\text{Nav}1.8$ immunoreactivity is correlated with an increase in TTX-R compound action potential at C fiber conduction velocity. A minor TTX-R, A fiber conduction velocity is also evident. These data demonstrate a functional reorganization of $\text{Nav}1.8$ along unmyelinated fibers and in some myelinated fibers. Antisense mediated knockdown of $\text{Nav}1.8$ immunoreactivity and TTX-R current in these uninjured axons correlate with the reversal of both mechanical and thermal hypersensitivity, suggesting that this reorganization of $\text{Nav}1.8$ activity along the uninjured axons may be necessary for expression of neuropathic pain in the injured rat (48). These as well as other data (112, 113), argue that abnormal activity in the uninjured primary afferent may be critical for the observed hypersensitivity to sensory input in the injured animal. A redistribution of $\text{Nav}1.8$ along the injured sciatic nerve has been also observed in the chronic constriction injury model of neuropathic pain (114), and $\text{Nav}1.8$ immunoreactivity is evident in peripheral nerve tissues from patients with chronic neuropathic pain (115, 116).

The use of antisense oligonucleotides to disrupt the expression and function of $\text{Nav}1.8$ has also been applied to other models of chronic inflammatory and visceral pain (85, 86). These findings further substantiate the role of $\text{Nav}1.8$ in the hypersensitivity of primary afferent neurons, suggesting that the changes in $\text{Nav}1.8$ seen in the L5/L6 spinal nerve injury model may have wider implications and potential clinical relevance.

Transgenic mice lacking $\text{Nav}1.8$ provide an alternative animal model to evaluate the role of $\text{Nav}1.8$ in neuropathic pain (41). Nerve injury elicits thermal hyperalgesia and tactile hypersensitivity by day 3 in both wild-type and $\text{Nav}1.8$ -null mutant mice, suggesting that neuropathic pain is developed and maintained despite the lack of $\text{Nav}1.8$ (117). An important confounding factor in the interpretation of the behavioral data in these animals, however, is the uncertain phenotype of the peripheral nervous system of these mice. The $\text{Nav}1.8$ -null mutant mice exhibit an upregulation of TTX-S $\text{Nav}1.7$ in the C type DRG neurons and modified activity of the C fibers (41). Other changes that may not be in common with the wild-type control after nerve injury may also occur. Complete elimination of the TTX-R current carried by $\text{Nav}1.8$ has a profound effect on the conductance of other channels, including sodium channel subtypes, the emergence of non- Na^+ action potentials,

and calcium channel activity (111). How these biophysical characteristics may influence the neurons' response to nerve injury is not known, making interpretation of data from this transgenic model difficult.

Nav1.9 and Neuropathic Pain

To date, there is little data implicating a role for Nav1.9 in neuropathic pain. In fact, there are two lines of evidence to suggest the channel contributes little to these behavioral changes. First, based on the kinetic properties of this channel and computer analysis, it has been proposed that this channel is active at the resting membrane potential and may modulate the resting potential of nociceptors and their response to subthreshold stimuli (43). However, under conditions of persistent excitability, most of these channels will be in the inactivated state and not available for opening. Second, antisense oligonucleotide that targets Nav1.9 shows that a knockdown of this channel subtype produces no effect on either thermal hyperalgesia or tactile hypersensitivity in the neuropathic rat (85). The antisense treatment in sham-operated rats also does not show any effect on baseline sensory thresholds.

SODIUM CHANNEL BLOCKERS AS ANTIHYPERALGESIC DRUGS

As mentioned above, a prominent role for VGSCs in the pathophysiology of an injured neuron is supported by the clinical effectiveness of agents that act primarily through a common, use-dependent block of sodium channels, e.g., local anesthetics, type 1b antiarrhythmics, and anticonvulsants (118), in the treatment of many types of chronic, in particular, neuropathic pain (119, 120).

Local Anesthetics/Antiarrhythmics

Although local anesthetic drugs have been considered as alternative therapy in certain types of acute pain (121–125), the predominant focus has been on chronic neuropathic pain syndromes, particularly because many of these appear unresponsive to treatment with standard opioids and nonsteroidal antiinflammatory drugs (119, 120). Local anesthetics have been reported to provide effective relief in painful diabetic polyneuropathy (126–128), neuralgic pain (129–132), lumbar radiculopathies (133, 134), complex regional pain syndrome (CRPS) I and II (135–137), and traumatic peripheral nerve injuries (138–141). A caveat, however, is that the majority of these studies represent clinical series and case reports, whereas only a comparatively small number involve randomized, single or double blind, placebo-controlled trials (142). Moreover, despite this capability for achieving efficacy in many different chronic, intractable pain conditions, the full analgesic potential of these agents has been frequently limited by the onset of numerous adverse, particularly CNS-related, side-effects, e.g., nausea and emesis, dizziness




Figure 2 Local anesthetic/type 1b antiarrhythmic drugs used as analgesics.

and light-headedness, somnolence, ataxia, and tinnitus. Cardiotoxicity can also be problematic particularly in the elderly population (143).

Intravenous lidocaine (Figure 2) is by far the most prevalent local anesthetic used for the treatment of neuropathic pain. In addition to the routine acute effect, it has been reported to produce pain relief for several days, an effect that far outlasts drug elimination from the plasma (128, 144, 145). The mechanism(s) related to this phenomenon are presently unknown. Other local anesthetics (see Figure 2) that have been used include flecainide (146, 147) and the oral agents tocainide (129) and type Ib antiarrhythmic agent, mexiletine (127, 139). Mexiletine, in particular, has been used relatively successfully either as a monotherapy or sequentially following an initial lidocaine infusion. Indeed, IV lidocaine has been increasingly advocated as a diagnostic aid for the presence of pain associated with nerve injury (132, 148) and for its predictive value of potential analgesic efficacy of oral local anesthetic agents, such as mexiletine for follow-up therapy (138, 141).

In animal models of neuropathic pain, the local anesthetics appear to have a similar profile to the clinical experience, being effective against mechanical and/or thermal hyperalgesia and tactile and/or cold allodynia but with differential sensitivity and limited efficacy (149–155). In most cases, the ceiling for the analgesic effect was almost always associated with the appearance of side effects, e.g., sedation; loss of righting reflex; and, at high doses, convulsions. In another model representative of facilitated processing of sensory information, the formalin test, lidocaine (149) and mexiletine (153) attenuated both phases of the behavioral response. A critical aspect of the local anesthetic analgesic action is the ability, at low subanesthetic (therapeutic) concentrations, to block the spontaneous and/or evoked repetitive, ectopic impulse activity in afferent fibers that is mediated by both TTX-S and the slowly inactivating TTX-R sodium channels (156–160).

Lidocaine can suppress the generation of this abnormal impulse traffic and restore normal firing rhythm by acting either directly at the site of origin or at distant sites (156–160). Consequently, these agents are able to target injured nerves on the basis of their high-frequency, repetitive firing characteristics, while having minimal impact on normal, somatosensory (i.e., nociceptive) neuronal function.

Anticonvulsants

Since Trousseau in 1885 noted that the paroxysmal component of trigeminal neuralgia was remarkably similar to epilepsy and termed it epileptiform neuralgia, anticonvulsant drugs (see Figure 3) have become among the more commonly used pharmacological interventions for the treatment of chronic pain (for reviews, see 161–163). It has been a common perception, possibly influenced by these early reports, that drugs of this class provide effective and sustained relief only when there is a paroxysmal, lancinating component to the pain, e.g., trigeminal neuralgia (164, 165). Although neuralgic pain remains a primary indication, carbamazepine and, to a more variable extent, diphenylhydantoin (also known as phenytoin) can also be effective analgesics in other types of painful, peripheral neuropathies, such as diabetic neuropathy (166–168). When effective, the general clinical impression of the established anticonvulsants has been that pain relief is almost always obtained concomitantly with numerous adverse side effects (164–166) and/or limitations in efficacy (165, 167). The adverse side-effect profile of these anticonvulsants can be severe and frequently includes CNS effects, such as dizziness, ataxia, lightheadedness, somnolence, and alterations in mood. Hepatic dysfunction and leukopenia have also been reported to occur with carbamazepine. The marginal analgesic efficacy of phenytoin and, to a lesser extent, carbamazepine at doses not associated with side effects is also reflected in most experimental animal models of peripheral nerve injury (150) and inflammation (169).

Recent years have seen the emergence of several novel antiepileptic agents, exemplified by lamotrigine (170), which may also have utility in the treatment of chronic pain but with a much improved therapeutic margin of safety over the established drugs, despite the possible need for higher doses than those required for anticonvulsant activity. Lamotrigine (Figure 3) produces a voltage- and




Figure 3 Anticonvulsant drugs used as analgesics.

frequency-dependent block of sodium channels with a subsequent reduction in the presynaptic release of the excitatory amino acids glutamate and aspartate (171, 172). Currently in Phase III trials for neuropathic pain, lamotrigine has been reported to show a promising analgesic effect in trigeminal neuralgia (173); diabetic neuropathy (174); and either postherpetic neuralgia, causalgia, or phantom limb pain (175). However, in a further randomized, double-blind, placebo-controlled study of intractable neuropathic pain, lamotrigine was found to be ineffective (176). Lamotrigine has been found to produce an antihyperalgesic and antiallodynic effect in the rodent models of neuropathic and/or inflammatory pain (169, 177–179), although the effect does appear to be modality specific. In acute pain models, lamotrigine appeared ineffective against an acute, high-threshold thermal noxious stimulus (177, 178), implying a selective interaction with pathways associated with pathophysiological events rather than with normal sensory nociceptive function consistent with its use-dependent block of sodium channels.

Voltage-Gated Sodium Channels in Sensory Neurons as Targets of Local Anesthetics and Anticonvulsants

A principal target of local anesthetic and anticonvulsant drugs in the most prevalent forms of neuropathic pain is most likely the sodium channels located in the peripheral sensory neuron. These channels may play an important role not only in the initial injury discharge but also in spontaneous, ongoing, and stimulus-evoked pain, and dysesthesias characteristic of many types of peripheral neuropathies. In clinical studies, lidocaine applied topically to either the skin (131, 180), region of the nerve supplying the painful foci (145, 181, 182), or neuroma (140) produced complete relief of spontaneous, ongoing, and stimulus-evoked pain. Moreover, in animal models of inflammatory and neuropathic pain, local application of bupivacaine produced a reversal of mechanical hyperalgesia (183) and allodynia (184), respectively. These studies would suggest, therefore, that in chronic pain of inflammatory or neuropathic origin, blockade of sodium channels in the sensory neurons constitutes an important site of action for the antihyperalgesic actions of these drugs.

CONCLUDING REMARKS

In summary, TTX-R sodium current is essential in the establishment of hyperexcitability of sensory neurons that contribute to inflammatory hyperalgesia and nerve injury-induced pain. Data support Nav1.8 as the predominant channel involved in gating this sodium current. It remains to be determined whether selective blockade of either Nav1.8 and/or Nav1.9 or, alternatively, any of the TTX-S channels in peripheral sensory neurons will produce either an improvement in analgesic efficacy or the therapeutic window over currently available nonsubtype selective agents. However, the discrete localization of the TTX-R channels, in particular

$\text{Na}_v1.8$, may be the crucial factor in providing a novel opportunity for drugs targeted at these channels to achieve both the desired degree of analgesic efficacy and safety profile.

The Annual Review of Pharmacology and Toxicology is online at
<http://pharmtox.annualreviews.org>

LITERATURE CITED

1. Cantrell AR, Catterall WA. 2001. Neuromodulation of Na^+ channels: an unexpected form of cellular plasticity. *Nat. Rev. Neurosci.* 2:397–407
2. Isom LL. 2001. Sodium channel beta subunits: anything but auxiliary. *Neuroscientist* 7:42–54
3. Goldin AL, Barchi RL, Caldwell JH, Hoffmann F, Howe JR, et al. 2000. Nomenclature of voltage-gated sodium channels. *Neuron* 28:365–68
4. Catterall WA. 2002. Molecular mechanisms of gating and drug block of sodium channels. *Novartis. Found. Symp.* 241:206–18, discussion 218–32
5. Yu FH, Catterall WA. 2003. Overview of the voltage-gated sodium channel family. *Genome Biol.* 4:207
6. Meyer RA, Campbell JN, Raja SN. 1994. Peripheral neural mechanisms of nociception. In *Textbook of Pain*, ed. PD Wall, R Melzack, pp. 13–56. New York: Churchill Livingstone
7. Schmelz M, Schmid R, Handwerker HO, Torebjork HE. 2000. Encoding of burning pain from capsaicin-treated human skin in two categories of unmyelinated nerve fibres. *Brain* 123(Pt. 3):560–71
8. Djouhri L, Newton R, Levinson SR, Berry CM, Carruthers B, Lawson SN. 2003. Sensory and electrophysiological properties of guinea-pig sensory neurones expressing $\text{Na}(\text{v})1.7$ (PN1) $\text{Na}(+)$ channel alphasubunit protein. *J. Physiol.* 546:565–76
9. Fang X, Djouhri L, Okuse K, Wood JN, Lawson SN. 2001. Sensory and electrophysiological properties of DRG neu-
- rones with SNS-like immunoreactivity (SNS-Li) in rats. *Soc. Neurosci. Abstr.* 27:Program 819.815
10. Fang X, Djouhri L, Black JA, Dib-Hajj SD, Waxman SG, Lawson SN. 2002. The presence and role of the tetrodotoxin-resistant sodium channel $\text{Na}(\text{v})1.9$ (NaN) in nociceptive primary afferent neurons. *J. Neurosci.* 22:7425–33
11. Quasthoff S, Grosskreutz J, Schroder JM, Schneider U, Graw P. 1995. Calcium potentials and tetrodotoxin-resistant sodium potentials in unmyelinated C fibres of biopsied human sural nerve. *Neuroscience* 69:955–65
12. Brock JA, McLachlan EM, Belmonte C. 1998. Tetrodotoxin-resistant impulses in single nociceptor nerve terminals in guinea-pig cornea. *J. Physiol. (London)* 512:211–17
13. Scroggs RS, Fox AP. 1992. Calcium current variation between acutely isolated adult rat dorsal root ganglion neurons of different size. *J. Physiol.* 445:639–58
14. Baccaglini PI, Hogan PG. 1983. Some rat sensory neurons in culture express characteristics of differentiated pain sensory cells. *Proc. Natl. Acad. Sci. USA* 80:594–98
15. Gold MS, Dastmalchi S, Levine JD. 1996. Co-expression of nociceptor properties in dorsal root ganglion neurons from the adult rat *in vitro*. *Neuroscience* 71:265–75
16. Stucky C, Lewin GR. 1999. Isolectin B(4)-positive and -negative nociceptors are functionally distinct. *J. Neurosci.* 19: 6497–505

17. Petruska JC, Cooper BY, Gu JG, Rau KK, Johnson RD. 2000. Distribution of P2X1, P2X2, and P2X3 receptor subunits in rat primary afferents: relation to population markers and specific cell types. *J. Chem. Neuroanat.* 20:141–62
18. Petruska JC, Cooper BY, Johnson RD, Gu JG. 2000. Distribution patterns of different P2x receptor phenotypes in acutely dissociated dorsal root ganglion neurons of adult rats. *Exp. Brain Res.* 134:126–32
19. Petruska JC, Napaporn J, Johnson RD, Gu JG, Cooper BY. 2000. Subclassified acutely dissociated cells of rat DRG: histochemistry and patterns of capsaicin-, proton-, and ATP-activated currents. *J. Neurophysiol.* 84:2365–79
20. Petruska JC, Napaporn J, Johnson RD, Cooper BY. 2002. Chemical responsiveness and histochemical phenotype of electrophysiologically classified cells of the adult rat dorsal root ganglion. *Neuroscience* 115:15–30
21. Harper AA, Lawson SN. 1985. Conduction velocity is related to morphological cell type in rat dorsal root ganglion neurones. *J. Physiol.* 359:31–46
22. Lee KH, Chung K, Chung JM, Coggeshall RE. 1986. Correlation of cell body size, axon size, and signal conduction velocity for individually labeled dorsal root ganglion cells in the cat. *J. Comp. Neurol.* 243:335–46
23. Lawson SN, Perry MJ, Prabhakar E, McCarthy PW. 1993. Primary sensory neurones: neurofilament, neuropeptides, and conduction velocity. *Brain Res. Bull.* 30: 239–43
24. Ritter AM, Mendell LM. 1992. Somal membrane properties of physiologically identified sensory neurons in the rat: effects of nerve growth factor. *J. Neurophysiol.* 68:2033–41
25. Black JA, Dib-Hajj S, McNabola K, Jeste S, Rizzo MA, et al. 1996. Spinal sensory neurons express multiple sodium channel alpha-subunit mRNAs. *Brain Res. Mol. Brain Res.* 43:117–31
26. Renganathan M, Dib-Hajj S, Waxman SG. 2002. Na(v)1.5 underlies the 'third TTX-R sodium current' in rat small DRG neurons. *Brain Res. Mol. Brain Res.* 106: 70–82
27. Shah BS, Stevens EB, Gonzalez MI, Bramwell S, Pinnock RD, et al. 2000. Beta3, a novel auxiliary subunit for the voltage-gated sodium channel, is expressed preferentially in sensory neurons and is upregulated in the chronic constriction injury model of neuropathic pain. *Eur. J. Neurosci.* 12:3985–90
28. Kazen-Gillespie KA, Ragsdale DS, D'Andrea MR, Mattei LN, Rogers KE, Isom LL. 2000. Cloning, localization, and functional expression of sodium channel beta1A subunits. *J. Biol. Chem.* 275: 1079–88
29. Waxman SG, Kocsis JD, Black JA. 1994. Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. *J. Neurophysiol.* 72:466–70
30. Caldwell JH, Schaller KL, Lasher RS, Peles E, Levinson SR. 2000. Sodium channel Na(v)1.6 is localized at nodes of ranvier, dendrites, and synapses. *Proc. Natl. Acad. Sci. USA* 97:5616–20
31. Toledo AJ, Brehm P, Halegoua S, Mandel G. 1995. A single pulse of nerve growth factor triggers long-term neuronal excitability through sodium channel gene induction. *Neuron* 14:607–11
32. Fjell J, Hjelmstrom P, Hormuzdiar W, Milenkovic M, Aglieco F, et al. 2000. Localization of the tetrodotoxin-resistant sodium channel NaN in nociceptors. *Neuroreport* 11:199–202
33. Ogata N, Tatebayashi H. 1993. Kinetic analysis of two types of Na⁺ channels in rat dorsal root ganglia. *J. Physiol. (London)* 466:9–37
34. Cummins TR, Waxman SG. 1997. Downregulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-sensitive

sodium current in small spinal sensory neurons after nerve injury. *J. Neurosci.* 17:3503–14

35. Rush AM, Brau ME, Elliott AA, Elliott JR. 1998. Electrophysiological properties of sodium current subtypes in small cells from adult rat dorsal root ganglia. *J. Physiol. (London)* 511:771–89

36. Scholz A, Appel N, Vogel W. 1998. Two types of TTX-resistant and one TTX-sensitive Na^+ channel in rat dorsal root ganglion neurons and their blockade by halothane. *Suppl. Eur. J. Neurosci.* 10:2547–56

37. Kostyuk PG, Veselovsky NS, Fedulova SA, Tsyndrenko AY. 1981. Ionic currents in the somatic membrane of rat dorsal root ganglion neurons—I. Sodium currents. *Neuroscience* 6:2424–30

38. Roy ML, Narahashi T. 1992. Differential properties of tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels in rat dorsal root ganglion neurons. *J. Neurosci.* 12:2104–11

39. Elliott AA, Elliott JR. 1993. Characterization of TTX-sensitive and TTX-resistant sodium currents in small cells from adult rat dorsal root ganglia. *J. Physiol. (London)* 463:39–56

40. Cummins TR, Dib-Hajj SD, Black JA, Akopian AN, Wood JN, Waxman SG. 1999. A novel persistent tetrodotoxin-resistant sodium current in SNS-null and wild-type small primary sensory neurons. *J. Neurosci.* 19:1–6

41. Akopian AN, Souslova V, England S, Okuse K, Ogata N, et al. 1999. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. *Nat. Neurosci.* 2:541–48

42. Baker MD, Chandra SY, Ding Y, Waxman SG, Wood JN. 2003. GTP-induced tetrodotoxin-resistant Na^+ current regulates excitability in mouse and rat small diameter sensory neurones. *J. Physiol. (London)* 548:373–82

43. Herzog RI, Cummins TR, Waxman SG. 2001. Persistent TTX-resistant Na^+ current affects resting potential and response to depolarization in simulated spinal sensory neurons. *J. Neurophysiol.* 86:1351–64

44. Dib-Hajj SD, Tyrrell L, Black JA, Waxman SG. 1998. NaN, a novel voltage-gated Na^+ channel, is expressed preferentially in peripheral sensory neurons and down-regulated after axotomy. *Proc. Natl. Acad. Sci. USA* 95:8963–68

45. Tate S, Benn S, Hick C, Trezise D, John V, et al. 1998. Two sodium channels contribute to TTX-R sodium current in primary sensory neurons. *Nat. Neurosci.* 1: 653–55

46. Brau ME, Elliott JR. 1998. Local anaesthetic effects on tetrodotoxin-resistant Na^+ currents in rat dorsal root ganglion neurones. *Eur. J. Anaesthesiol.* 15:80–88

47. Gold MS, Thut PD. 2001. Lithium increases potency of lidocaine-induced block of voltage-gated Na^+ currents in rat sensory neurons *in vitro*. *J. Pharmacol. Exp. Ther.* 299:705–11

48. Gold MS, Weinreich D, Kim CS, Wang R, Treanor J, et al. 2003. Redistribution of $\text{Na}(\text{V})1.8$ in uninjured axons enables neuropathic pain. *J. Neurosci.* 23:158–66

49. England S, Bevan S, Docherty RJ. 1996. PGE2 modulates the tetrodotoxin-resistant sodium current in neonatal rat dorsal root ganglion neurons via the cyclic AMP-protein kinase A cascade. *J. Physiol. (London)* 495:429–40

50. Blair NT, Bean BP. 2002. Roles of tetrodotoxin (TTX)-sensitive Na^+ current, TTX-resistant Na^+ current, and Ca^{2+} current in the action potentials of nociceptive sensory neurons. *J. Neurosci.* 22:10277–90

51. Brock JA, Pianova S, Belmonte C. 2001. Differences between nerve terminal impulses of polymodal nociceptors and cold sensory receptors of the guinea-pig cornea. *J. Physiol.* 533:493–501

52. Carr RW, Pianova S, Brock JA. 2002. The effects of polarizing current on nerve terminal impulses recorded from polymodal

and cold receptors in the guinea-pig cornea. *J. Gen. Physiol.* 120:395–405

53. Gu JG, MacDermott AB. 1997. Activation of ATP P2X receptors elicits glutamate release from sensory neuron synapses. *Nature* 389:749–53

54. Samad TA, Sapirstein A, Woolf CJ. 2002. Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets. *Trends Mol. Med.* 8:390–96

55. Ferreira SH. 1972. Prostaglandins, aspirin-like drugs and analgesia. *Nat. New Biol.* 240:200–3

56. Handwerker HO. 1976. Influences of allogenic substances and prostaglandins on the discharges of unmyelinated cutaneous nerve fibers identified as nociceptors. *Adv. Pain Res. Ther.* 1:41–45

57. Chahl LA, Iggo A. 1977. The effects of bradykinin and prostaglandin E1 on rat cutaneous afferent nerve activity. *Br. J. Pharmacol.* 59:343–47

58. Khasar SG, Gold MS, Levine JD. 1998. A tetrodotoxin-resistant sodium current mediates inflammatory pain in the rat. *Neurosci. Lett.* 256:17–20

59. Gold MS, Reichling DB, Shuster MJ, Levine JD. 1996. Hyperalgesic agents increase a tetrodotoxin-resistant Na^+ current in nociceptors. *Proc. Natl. Acad. Sci. USA* 93:1108–12

60. Cardenas LM, Cardenas CG, Scroggs RS. 2001. 5HT increases excitability of nociceptor-like rat dorsal root ganglion neurons via cAMP-coupled TTX-resistant Na^+ channels. *J. Neurophysiol.* 86:241–48

61. Okamoto K, Imbe H, Morikawa Y, Itoh M, Sekimoto M, et al. 2002. 5-HT2A receptor subtype in the peripheral branch of sensory fibers is involved in the potentiation of inflammatory pain in rats. *Pain* 99:133–43

62. D'Alcantara P, Cardenas LM, Swillens S, Scroggs RS. 2002. Reduced transition between open and inactivated channel states underlies 5-HT increased INa^+ in rat nociceptors. *Biophys. J.* 83:5–21

63. Cui M, Nicol GD. 1995. Cyclic AMP mediates the prostaglandin E2-induced potentiation of bradykinin excitation in rat sensory neurons. *Neuroscience* 66:459–66

64. Zhou Z, Davar G, Strichartz G. 2002. Endothelin-1 (ET-1) selectively enhances the activation gating of slowly inactivating tetrodotoxin-resistant sodium currents in rat sensory neurons: a mechanism for the pain-inducing actions of ET-1. *J. Neurosci.* 22:6325–30

65. Ferreira SH, Romitelli M, de Nucci G. 1989. Endothelin-1 participation in overt and inflammatory pain. *J. Cardiovasc. Pharmacol.* 13(Suppl. 5):S220–22

66. Griswold DE, Douglas SA, Martin LD, Davis TG, Davis L, et al. 1999. Endothelin B receptor modulates inflammatory pain and cutaneous inflammation. *Mol. Pharmacol.* 56:807–12

67. Piovezan AP, D'Orleans-Juste P, Souza GE, Rae GA. 2000. Endothelin-1-induced ET(A) receptor-mediated nociception, hyperalgesia and oedema in the mouse hind-paw: modulation by simultaneous ET(B) receptor activation. *Br. J. Pharmacol.* 129:961–68

68. Gokin AP, Fareed MU, Pan HL, Hans G, Strichartz GR, Davar G. 2001. Local injection of endothelin-1 produces pain-like behavior and excitation of nociceptors in rats. *J. Neurosci.* 21:5358–66

69. Khasar SG, McCarter G, Levine JD. 1999. Epinephrine produces a beta-adrenergic receptor-mediated mechanical hyperalgesia and in vitro sensitization of rat nociceptors. *J. Neurophysiol.* 81:1104–12

70. Lewin GR, Ritter AM, Mendell GR. 1993. Nerve growth factor-induced hyperalgesia in the neonatal and adult rat. *J. Neurosci.* 13:2136–48

71. Shu X, Mendell GR. 1999. Nerve growth factor acutely sensitizes the response of adult rat sensory neurons to capsaicin. *Neurosci. Lett.* 274:159–62

72. Winston J, Toma H, Shenoy M, Pasricha PJ. 2001. Nerve growth factor

regulates VR-1 mRNA levels in cultures of adult dorsal root ganglion neurons. *Pain* 89:181–86

73. Bielefeldt K, Ozaki N, Gebhart GF. 2003. Role of nerve growth factor in modulation of gastric afferent neurons in the rat. *Am. J. Physiol. Gastro. Liver Physiol.* 284:G499–507

74. Zhang YH, Vasko MR, Nicol GD. 2002. Ceramide, a putative second messenger for nerve growth factor, modulates the TTX-resistant Na^+ current and delayed rectifier K^+ current in rat sensory neurons. *J. Physiol.* 544:385–402

75. Fjell J, Cummins TR, Dib-Hajj SD, Fried K, Black JA, Waxman SG. 1999. Differential role of GDNF and NGF in the maintenance of two TTX-resistant sodium channels in adult DRG neurons. *Mol. Brain Res.* 67:267–82

76. Cho HJ, Kim SY, Park MJ, Kim DS, Kim JK, Chu MY. 1997. Expression of mRNA for brain-derived neurotrophic factor in the dorsal root ganglion following peripheral inflammation. *Brain Res.* 749:358–62

77. Kafitz KW, Rose CR, Thoenen H, Konnerth A. 1999. Neurotrophin-evoked rapid excitation through TrkB receptors. *Nature* 401:918–21

78. Blum R, Kafitz KW, Konnerth A. 2002. Neurotrophin-evoked depolarization requires the sodium channel $\text{Na}(\text{V})1.9$. *Nature* 419:687–93

79. Waxman SG, Dib-Hajj S, Cummins TR, Black JA. 1999. Sodium channels and pain. *Proc. Natl. Acad. Sci. USA* 96:7635–39

80. Gould HJ 3rd, England JD, Liu ZP, Levinson SR. 1998. Rapid sodium channel augmentation in response to inflammation induced by complete Freund's adjuvant. *Brain Res.* 802:69–74

81. Tanaka M, Cummins TR, Ishikawa K, Dib-Hajj SD, Black JA, Waxman SG. 1998. SNS Na^+ channel expression increases in dorsal root ganglion neurons in the carrageenan inflammatory pain model. *Neuroreport* 9:967–72

82. Weskamp G, Otten U. 1987. An enzyme-linked immunoassay for nerve growth factor (NGF): a tool for studying regulatory mechanisms involved in NGF production in brain and in peripheral tissues. *J. Neurochem.* 48:1779–86

83. Woolf CJ, Safieh-Garabedian B, Ma QP, Crilly P, Winter J. 1994. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. *Neuroscience* 62:327–31

84. Bielefeldt K, Ozaki N, Gebhart GF. 2002. Experimental ulcers alter voltage-sensitive sodium currents in rat gastric sensory neurons. *Gastroenterology* 122:394–405

85. Porreca F, Lai J, Bian D, Wegert S, Ossipov MH, et al. 1999. A comparison of the potential role of the tetrodotoxin-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain. *Proc. Natl. Acad. Sci. USA* 96:7640–44

86. Yoshimura N, Seki S, Novakovic SD, Tzoumaka E, Erickson VL, et al. 2001. The involvement of the tetrodotoxin-resistant sodium channel Nav1.8 (PN3/SNS) in a rat model of visceral pain. *J. Neurosci.* 21:8690–96

87. Toledo-Aral JJ, Moss BL, He ZJ, Koszowski AG, Whisenand T, et al. 1997. Identification of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral neurons. *Proc. Natl. Acad. Sci. USA* 94:1527–32

88. Devor M, Keller CH, Deerinck TJ, Ellisman MH. 1989. Na^+ channel accumulation on axolemma of afferent endings in nerve end neuromas in *Apterodonotus*. *Neurosci. Lett.* 102:149–54

89. England JD, Happel LT, Kline DG, Gamboni F, Thouron CL, et al. 1996. Sodium channel accumulation in humans with painful neuromas. *Neurology* 47:272–76

90. Devor M. 1994. In *Textbook of Pain*, ed. PD Walls, R Melzack, pp. 79–101. Edinburgh: Churchill Livingstone

91. Waxman SG, Kocsis JD, Black JA. 1994. Type III sodium channel mRNA

is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. *J. Neurophysiol.* 72:466–70

92. Black JA, Cummins TR, Plumpton C, Chen YH, Hormuzdiar W, et al. 1999. Upregulation of a silent sodium channel after peripheral, but not central, nerve injury in DRG neurons. *J. Neurophysiol.* 82:2776–85

93. Everill B, Cummins TR, Waxman SG, Kocsis JD. 2001. Sodium currents of large (A β type) adult cutaneous afferent dorsal root ganglion neurons display rapid recovery from inactivation before and after axotomy. *Neuroscience* 106:161–69

94. Sleeper AA, Cummins TR, Dib-Hajj SD, Hormuzdiar W, Tyrrell L, et al. 2000. Changes in expression of two tetrodotoxin-resistant sodium channels and their currents in dorsal root ganglion neurons after sciatic nerve injury but not rhizotomy. *J. Neurosci.* 20:7279–89

95. Decosterd I, Ji RR, Abdi S, Tate S, Woolf CJ. 2002. The pattern of expression of the voltage-gated sodium channels Nav1.8 and Nav1.9 does not change in uninjured primary sensory neurons in experimental neuropathic pain models. *Pain* 96:269–77

96. Lancaster E, Weinreich D. 2001. Sodium channels in vagotomized primary afferent neurons of the rat. *J. Physiol.* 536:445–58

97. Kim SH, Chung JM. 1992. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. *Pain* 50:355–63

98. Bennet GJ, Xie YK. 1988. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. *Pain* 33:87–107

99. Decosterd I, Woolf CJ. 2000. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. *Pain* 87:149–58

100. Seltzer Z, Dubner R, Shir Y. 1990. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. *Pain* 43:205–18

101. Winkelstein BA, Rutkowski MD, Weinstein JN, DeLeo JA. 2001. Quantification of neural tissue injury in a rat radiculopathy model: comparison of local deformation, behavioral outcomes, and spinal cytokine mRNA for two surgeons. *J. Neurosci. Methods* 111:49–57

102. Liu X, Eschenfelder S, Blenk KH, Janig W, Habler HJ. 2000. Spontaneous activity of axotomized afferent neurons after L5 spinal nerve injury in rats. *Pain* 84:309–18

103. Liu CN, Wall PD, Ben-Dor E, Michaelis M, Amir R, Devor M. 2000. Tactile allodynia in the absence of C-fiber activation: altered firing properties of DRG neurons following spinal nerve injury. *Pain* 85:503–21

104. Han HC, Lee DH, Chung JM. 2000. Characteristics of ectopic discharges in a rat neuropathic pain model. *Pain* 84:253–61

105. Boucher TJ, Okuse K, Bennett DL, Munson JB, Wood JN, McMahon SB. 2000. Potent analgesic effects of GDNF in neuropathic pain states. *Science* 290:124–27

106. Kim CH, Oh Y, Chung JM, Chung K. 2001. The changes in expression of three subtypes of TTX-sensitive sodium channels in sensory neurons after spinal nerve ligation. *Mol. Brain Res.* 95:153–61

107. Wang R, Guo W, Ossipov MH, Vanderah TW, Porreca F, Lai J. 2003. GDNF normalizes neurochemical changes in injured dorsal root ganglion neurons and prevents the expression of experimental neuropathic pain. *Neuroscience*. In press

108. Lyu YS, Park SK, Chung K, Chung JM. 2000. Low dose of tetrodotoxin reduces neuropathic pain behaviors in an animal model. *Brain Res.* 871:98–103

109. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. 1994. Quantitative assessment of tactile allodynia in the rat paw. *J. Neurosci. Methods* 53:55–63

110. Lai J, Gold MS, Kim CS, Bian D, Ossipov MH, et al. 2002. Inhibition of neuropathic pain by decreased expression of

the tetrodotoxin resistant sodium channel, $\text{Na}_V1.8$. *Pain* 95:143–52

111. Renganathan M, Cummins TR, Waxman SG. 2001. Contribution of $\text{Na}_V1.8$ sodium channels to action potential electrogenesis in DRG neurons. *J. Neurophysiol.* 86:629–40
112. Wu G, Ringkamp M, Murinson BB, Pogatzki EM, Hartke TV, et al. Degeneration of myelinated efferent fibers induces spontaneous activity in uninjured C-fiber afferents. *J. Neurosci.* 22:7746–53
113. Li Y, Dorsi MJ, Meyer RA, Belzberg AJ. 2000. Mechanical hyperalgesia after an L5 spinal nerve lesion in the rat is not dependent on input from injured nerve fibers. *Pain* 85:493–502
114. Novakovic SD, Tzoumaka E, McGivern JG, Haraguchi M, Sangameswaran L, et al. 1998. Distribution of the tetrodotoxin-resistant sodium channel PN3 in rat sensory neurons in normal and neuropathic conditions. *J. Neurosci.* 18:2174–87
115. Coward K, Plumpton C, Facer P, Birch R, Carlstedt T, et al. 2000. Immunolocalization of SNS/PN3 and $\text{Na}^+/$ SNS2 sodium channels in human pain states. *Pain* 85:41–50
116. Bucknill AT, Coward K, Plumpton C, Tate, S, Bountra C, et al. 2002. Nerve fibers in lumbar spine structures and injured spinal roots express the sensory neuron-specific sodium channels SNS/PN3 and $\text{Na}^+/$ SNS2. *Spine* 27:135–40
117. Kerr BJ, Souslova V, McMahon SB, Wood JN. 2001. A role for the TTX-resistant sodium channel $\text{Na}_V1.8$ in NGF-induced hyperalgesia, but not neuropathic pain. *Neuroreport* 12:1–4
118. Catterall WA. 1987. Common modes of drug action on Na^+ channels: local anesthetics, antiarrhythmics and anticonvulsants. *Trends Pharmacol. Sci.* 8:57–65
119. Backonja MM. 1994. Local anesthetics as adjuvant analgesics. *J. Pain Symp. Manage.* 9:491–99
120. Tanelian DL, Victory RA. 1995. Sodium channel-blocking agents: their use in neuropathic pain conditions. *Pain Forum* 4:75–80
121. Elleemann K, Sjogren P, Banning AM, Jensen TS, Smith T, Geertsen P. 1989. Trial of intravenous lidocaine on painful neuropathy in cancer patients. *Clin. J. Pain* 5:291–94
122. Brose WG, Cousins MJ. 1991. Subcutaneous lidocaine for treatment of neuropathic cancer pain. *Pain* 45:145–48
123. Bruera E, Ripamonti C, Brenneis C, Macmillan K, Hanson J. 1992. A randomized double-blind crossover trial of intravenous lidocaine in the treatment of neuropathic cancer pain. *J. Pain Symp. Manage.* 7:138–40
124. Petersen P, Kastrup J. 1987. Dercum's disease (adiposis dolorosa). Treatment of the severe pain with intravenous lidocaine. *Pain* 28:77–80
125. Kaube H, Hoskin KL, Goadsby PJ. 1994. Lignocaine and headache: an electrophysiological study in the cat with supporting clinical observations in man. *J. Neurol.* 241:415–20
126. Kastrup J, Petersen P, Dejgaard A, Angelo HR, Hilsted J. 1987. Intravenous lidocaine infusion—a new treatment of chronic painful diabetic neuropathy? *Pain* 28:69–75
127. Dejgaard A, Petersen P, Kastrup J. 1988. Mexiletine for treatment of chronic painful diabetic neuropathy. *Lancet* 1:9–11
128. Bach FW, Jensen TS, Kastrup J, Stigsby B, Dejgaard A. 1990. The effect of intravenous lidocaine on nociceptive processing in diabetic neuropathy. *Pain* 40:29–34
129. Lindstrom P, Lindblom U. 1987. The analgesic effect of tocainide in trigeminal neuralgia. *Pain* 28:45–50
130. Rowbotham MC, Reisner-Keller LA, Fields HL. 1991. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. *Neurology* 41: 1024–28
131. Rowbotham MC, Davies PS, Fields HL.

1995. Topical lidocaine gel relieves post-therapeutic neuralgia. *Ann. Neurol.* 37:246–53

132. Marchettini P, Lacerenza M, Marangoni C, Pellegata G, Sotgiu ML, Smirne S. 1992. Lidocaine test in neuralgia. *Pain* 48:377–82

133. Nagaro T, Shimizu C, Inoue H, Fujitani T, Adachi N, et al. 1995. The efficacy of intravenous lidocaine on various types of neuropathic pain. *Jap. J. Anesth.* 44:862–67

134. Ferrante FM, Paggioli J, Cherukuri S, Arthur GR. 1996. The analgesic response to intravenous lidocaine in the treatment of neuropathic pain. *Anesth. Analg.* 82:91–97

135. Edwards WT, Habib F, Burney RG, Begin G. 1985. Intravenous lidocaine in the management of various chronic pain states. A review of 211 cases. *Reg. Anesth.* 10:1–6

136. Galer BS, Miller KV, Rowbotham MC. 1993. Response to intravenous lidocaine infusion differs based on clinical diagnosis and site of nervous system injury. *Neurology* 43:1233–35

137. Wallace MS, Ridgeway BM, Leung AY, Gerayli A, Yaksh TL. 2000. Concentration-effect relationship of intravenous lidocaine on the allodynia of complex regional pain syndrome types I and II. *Anesthesiology* 92:75–83

138. Tanelian DL, Brose WG. 1991. Neuropathic pain can be relieved by drugs that are use-dependent sodium channel blockers: lidocaine, carbamazepine, and mexiletine. *Anesthesiology* 74:949–51

139. Chabal C, Jacobson L, Mariano A, Chaney E, Britell CW. 1992. The use of oral mexiletine for the treatment of pain after peripheral nerve injury. *Anesthesiology* 76:513–17

140. Chabal C, Jacobson L, Russell LC, Burchiel KJ. 1992. Pain response to perineuromal injection of normal saline, epinephrine, and lidocaine in humans. *Pain* 49:9–12

141. Galer BS, Harle J, Rowbotham MC. 1996. Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: a prospective study. *J. Pain Symp. Manage.* 12:161–67

142. Kingery WS. 1997. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. *Pain* 73:123–39

143. Covino BG, Wildsmith JAW. 1998. Clinical pharmacology of local anesthetic agents. In *Neural Blockade in Clinical Anesthesia and Management of Pain*, ed. MJ Cousins, PO Bridenbaugh, pp. 97–128. Philadelphia: Lippincott-Raven. 3rd ed.

144. Petersen P, Kastrup J, Zeeberg I, Boysen G. 1986. Chronic pain treatment with intravenous lidocaine. *Neurol. Res.* 8:189–90

145. Arner S, Lindblom U, Meyerson BA, Molander C. 1990. Prolonged relief of neuralgia after regional anesthetic blocks. A call for further experimental and systematic clinical studies. *Pain* 43:287–97

146. Sinnott C, Edmonds P, Cropley I, Hanks G, Dunlop RJ, et al. 1991. Flecainide in cancer nerve pain. *Lancet* 337:1347

147. Ichimata M, Ikebe H, Yoshitake S, Hattori S, Iwasaka H, Noguchi T. 2001. Analgesic effects of flecainide on posttherapeutic neuralgia. *Int. J. Clin. Pharmacol. Res.* 21:15–19

148. Mao J, Chen LL. 2000. Systemic lidocaine for neuropathic pain relief. *Pain* 87:7–17

149. Abram SE, Yaksh TL. 1994. Systemic lidocaine blocks nerve injury-induced hyperalgesia and nociceptor-driven spinal sensitization in the rat. *Anesthesiology* 80: 383–91

150. Koch BD, Faurot GF, McGuirk JR, Clarke DE, Hunter JC. 1996. Modulation of mechano-hyperalgesia by clinically effective analgesics in rats with a peripheral mononeuropathy. *Analgesia* 2:157–64

151. Chaplan SR, Bach FW, Shaffer SL, Yaksh TL. 1995. Prolonged alleviation of tactile allodynia by intravenous lidocaine in neuropathic rats. *Anesthesiology* 83:775–85

152. Hedley LR, Martin B, Waterbury LD, Clarke DE, Hunter JC. 1995. A comparison of the action of mexilitine and morphine in rodent models of acute and chronic pain. *Proc. West Pharmacol. Soc.* 38:103–4

153. Jett MF, McGuirk J, Waligora D, Hunter JC. 1997. The effects of mexilitine, desipramine and fluoxetine in rat models involving central sensitization. *Pain* 69:161–69

154. Nozaki-Taguchi N, Chaplan SR, Higuera ES, Ajakwe RC, Yaksh TL. 2001. Vin-cristine-induced allodynia in the rat. *Pain* 93:69–76

155. Smith LJ, Shih A, Miletic G, Miletic V. 2002. Continual systemic infusion of lidocaine provides analgesia in an animal model of neuropathic pain. *Pain* 97:267–73

156. Matzner O, Devor M. 1994. Hyperexcitability at sites of nerve injury depends on voltage-sensitive Na^+ channels. *J. Neurophysiol.* 72:349–59

157. Chabal C, Russell LC, Burchiel KJ. 1989. The effect of intravenous lidocaine, tocainide, and mexiletine on spontaneously active fibers originating in rat sciatic neuromas. *Pain* 38:333–38

158. Devor M, Wall PD, Catalan N. 1992. Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction. *Pain* 48:261–68

159. Omana-Zapata I, Khabbaz M, Hunter JC, Bley KR. 1997. QX-314 inhibits ectopic nerve activity associated with neuropathic pain. *Brain Res.* 771:228–37

160. Persaud N, Strichartz GR. 2002. Micromolar lidocaine selectively blocks propagating ectopic impulses at a distance from their site of origin. *Pain* 99:333–40

161. Swerdlow M. 1984. Anticonvulsant drugs and chronic pain. *Clin. Neuropharmacol.* 7:51–82

162. Blom S. 1962. Trigeminal neuralgia: its treatment with a new anticonvulsant drug (G-32883). *Lancet* 1:839–40

163. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A. 1995. Anticonvulsant drugs for the management of pain: a systematic review. *Br. Med. J.* 311:1047–52

164. Campbell FG, Graham JG, Zilkha KJ. 1966. Clinical trial of carbamazepine (Tegretol) in trigeminal neuralgia. *J. Neurol. Neurosurg. Psychiatry* 29:265–67

165. Killian JM, Fromm GH. 1968. Carbamazepine in the treatment of neuralgia. Use of side-effects. *Arch. Neurol.* 19:129–36

166. Rull J, Quibrera R, Gonzalez-Millan H, Lozano Castenada O. 1969. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine: double-blind crossover study. *Diabetologia* 5:215–20

167. Sudek CD, Werns S, Reidenberg MM. 1977. Phenytoin in the treatment of diabetic symmetrical polyneuropathy. *Clin. Pharmacol. Ther.* 22:196–99

168. Chadda VS, Mathur MS. 1978. Double blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy. *J. Assoc. Physicians India* 26:403–6

169. Nakamura-Craig M, Follenfant RL. 1995. Effect of lamotrigine in the acute and chronic hyperalgesia induced by PGE_2 and in the chronic hyperalgesia in rats with streptozotocin-induced diabetes. *Pain* 63:33–37

170. Fitton A, Goa KL. 1995. Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. *Drugs* 50:691–713

171. Leach MJ, Marden CM, Miller AA. 1986. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug. II. Neurochemical studies on the mechanism of action. *Epilepsia* 27:490–97

172. Cheung H, Kamp D, Harris E. 1992. An *in vitro* investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. *Epilepsy Res.* 13:107–12

173. Zakrzewska JM, Chaudhry Z, Nurmiikko TJ, Patton DW, Mullens EL. 1997. Lamotrigine (Lamictal) in refractory trigeminal neuralgia: results from a double-blind

placebo controlled crossover trial. *Pain* 73:223–30

174. Eisenberg E, Alon N, Yarnitsky D, Ishay A, Daoud D. 1996. Lamotrigine for the treatment of painful diabetic neuropathy. *8th World Congress on Pain Abstr*, Vancouver, Canada. p. 372.

175. Harbison J, Dennehy F, Keating D. 1997. Lamotrigine for pain with hyperalgesia. *Irish Med. J.* 90:56

176. McCleane G. 1999. 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: a randomized, double-blind, placebo controlled trial. *Pain* 83:105–7

177. Hunter JC, Gogas KR, Hedley LR, Jacobson LO, Kassotakis L, et al. 1997. The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. *Eur. J. Pharmacol.* 324:153–60

178. Laughlin TM, Tram KV, Wilcox GL, Birnbaum AK. 2002. Comparison of antiepileptic drugs tiagabine, lamotrigine and gabapentin in mouse models of acute, prolonged and chronic nociception. *J. Pharmacol. Exp. Ther.* 302:1168–75

179. Lee TH, Wang CJ, Wu PC, Buerkle H, Lin SH, Yang LC. 2002. The thermal and mechanical anti-hyperalgesic effects of pre- versus post-intrathecal treatment with lamotrigine in a rat model of inflammatory pain. *Life Sci.* 70:3039–47

180. Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. 2002. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with the use of the neuropathic pain scale. *Clin. J. Pain* 18:297–301

181. Gracely RH, Lynch SA, Bennett GJ. 1992. Painful neuropathy: altered central processing maintained dynamically by peripheral input. *Pain* 51:175–94

182. Koltzenburg M, Torebjork HE, Wahren LK. 1994. Nociceptor modulated central sensitization causes mechanical hyperalgesia in acute chemogenic and chronic neuropathic pain. *Brain Res.* 117:579–91

183. Fletcher D, Le Corre P, Guilbaud G, Le Verge R. 1997. Antinociceptive effect of bupivacaine encapsulated in poly(D,L)-lactide-co-glycolide microspheres in the acute inflammatory pain model of carrageenan-injected rats. *Anesth. Analg.* 84:90–4

184. Yoon YW, Na HS, Chung JM. 1996. Contributions of injured and intact afferents to neuropathic pain in an experimental rat model. *Pain* 64:27–36